Recent developments in sialidase inhibitors for the treatment of influenza

Drugs of the Future

Volumn 23, Issue 10, 1998, Pages 1099-1109

  Bethell, Richard ^a   Smith, Paul ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; CARBAMIC ACID DERIVATIVE; OSELTAMIVIR; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR; ZANAMIVIR DERIVATIVE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; INFLUENZA; INHALATIONAL DRUG ADMINISTRATION; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POWDER INHALER; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS MUTATION; X RAY CRYSTALLOGRAPHY;

EID: 0031646322     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1998.023.10.858428     Document Type: Review

References (78)

1. Nicholson, K.G. Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990. Epidemiol Infect 1996, 116: 51-63.
2. Cox, N.J., Bender, C.A. The molecular epidemiology of influenza viruses. Semin Virol 1995, 6: 359-70.
3. Glezen, W.P. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982, 4: 25-44.
4. Meanwell, N.A., Krystal, M. Taking aim at a moving target -Inhibitors of influenza virus Part 1: Virus adsorption, entry and uncoating. Drug Discov Today 1996, 1: 316-24.
5. Whittington, A., Bethell, R. Recent developments in the antiviral therapy of influenza. Exp Opin Ther Pat 1995, 5: 793-803.
6. White, J.M., Hoffman, L.R., Arevalo, J.H., Wilson, I.A. Attachment and entry of influenza virus into host cells: Pivotal roles of the hemagglutinin. Struct Biol Viruses 1997, 80-104.
7. Hay, A.J. The action of adamantanamines against influenza A viruses: Inhibition of the M2 ion channel protein. Semin Virol 1992, 3: 21-30.
8. von Itzstein, M., Barry, J.G., Chong, A.K.J. The development of potential anti-influenza drugs. Curr Opin Ther Pat 1993, 3: 1755-62.
9. Hay, A.J. Potential targets and actions of antiviral agents against influenza viruses. Chem Scr 1986, 26: 77-81.
10. Bethell, R.C., Smith, P.W. Sialidase as a target for inhibitors of influenza virus replication. Exp Opin Invest Drugs 1997, 6: 1501-9.
11. Rotella, D.P. Influenza sialidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogs with potent anti-influenza activity. Chemtracts 1997, 10: 836-40.
12. Wade, R.C. "Flu" and structure-based drug design. Structure (London) 1997, 5: 1139-45.
13. Sham, H.L., Chen, X. Inhibitors of influenza virus sialidase and endonuclease. Curr Pharm Des 1997, 3: 159-68.
14. LaTessa, K.O., Press, J.B. A study of the active site of influenza virus sialidase: An approach to the rational design of novel anti-influenza drugs. Chemtracts 1997, 10: 330.
15. Smith, P.W., Cherry, P.C., Howes, P.C., Sollis, S.L., Taylor, N.R. New sialidase inhibitors for the treatment of influenza. Spec Publ - R Soc Chem 1997, 198(Anti-Infectives): 269-87.
16. von Itzstein, M., Thomson, R.J. Sialic acids recognising proteins: Drug discovery targets and potential glycopharmaceuticals. Curr Med Chem 1997, 4: 185-210.
17. Meanwell, N.A., Krystal, M. Taking aim at a moving target -Inhibitors of influenza virus part 2: Viral replication, packaging and release. Drug Discov Today 1996, 1: 388-97.
18. Taylor, G. Sialidases: Structures, biological significance and therapeutic potential. Curr Opin Struct Biol 1996, 6: 830-7.
19. Bamford, M.J. Sialidase inhibitors as potential anti-influenza drugs. J Enzyme Inhib 1995, 10: 1-16.
20. Colman, P.M. Design and antiviral properties of influenza virus sialidase inhibitors. Pure Appl Chem 1995, 67: 1683-8.
21. Varghese, J. Rational design of anti-influenza drugs. Chem Aust 1995, 62: 15.
22. Unverzagt, C. A sugar-based designer drug against influenza? Angew Chem 1993, 105: 1762-4. See also Angew Chem Int Ed Engl 1993, 32: 1691-3.
23. Unverzagt, C. A sugar-based designer drug against influenza? Angew Chem 1993, 105: 1762-4. See also Angew Chem Int Ed Engl 1993, 32: 1691-3.
24. Fromtling, R.A., Castaner, J. Zanamivir. Drugs Fut 1996, 21: 375-82.
25. Hayden, F.G., Treanor, J.J., Betts, R.F., Lobo, M., Esinhart, J.D., Hussey, E.K. Safety and efficacy of the sialidase inhibitor GG167 in experimental human influenza. JAMA 1996, 275: 295-9.
26. Hayden, F.G., Lobo, M., Hussey, E.K., Eason, C.U. Efficacy of intranasal GG167 in experimental human influenza A and B virus infection. Int Congr Ser 1996, 1123(Options for the Control of Influenza III): 718-25.
27. Hayden, F.G., Osterhaus, A.D.M.E., Treanor, J.J. et al. Efficacy and safety of the sialidase inhibitor zanamivir in the treatment of influenzavirus infections. New Engl J Med 1997, 337: 874-80.
28. Matsumoto, K., Nerome, K., Numasaki, Y., Oguri, K., Fukuda, T. Inhaled and intranasal GG167 in the treatment of influenza A and B: Preliminary results. Int Congr Ser 1996, 1123(Options for the Control of Influenza III): 713-7.
29. Kim, C.U., Lew, W., Williams, M.A. et al. Influenza sialidase inhibitors possessing a novel hydrophobia interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997, 119: 81-690.
30. Kati, W.M., Saldivar, A.S., Mohamadi, F., Sham, H.L., Laver, W.G., Kohlbrenner, W.E. GS4071 is a slow-binding inhibitor of influenza sialidase from both A and B strains. Biochem Biophys Res Commun 1998, 244: 408-13.
31. Mendel D.B., Tai, C.Y., Escarpe, P.A. et al. Oral administration of a prodrug of the influenza virus sialidase inhibitor GS4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 1998, 42: 640-6.
32. Li, W., Escarpe, P.A., Eisenberg, E.J. et al. Identification of GS4104 as an orally bioavailable prodrug of the influenza virus sialidase inhibitor GS4071. Antimicrob Agents Chemother 1998, 42: 647-53.
33. Eisenberg, E.J., Bidgood, A., Cundy, K.C. Penetration of GS4071, a novel influenza sialidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrob Agents Chemother 1997, 41: 1949-52.
34. Sidwell, R.W., Huffman, J.H., Barnard, D.L. et al. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus sialidase inhibitor. Antiviral Res 1998, 37: 107-20.
35. Ryan, D.M., Ticehurst, J., Dempsey, M.H. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob Agents Chemother 1995, 39: 2583-4.
36. Hayden, F.G., Lobo, M., Treanor, J.J., Miller, M., Mills, R.G. Efficacy and tolerability of oral GS4104 for early treatment of experiment influenza infection in humans. 37th Intersci Conf Antimicrob Agents Chemother (Sept. 28-Oct. 1, Toronto) 1997, Abst LB-26.
37. Kok, G.B., Campbell, M., Mickey, B., von Itzstein, M. Synthesis and biological evaluation of sulfur isosteres of the potent influenza virus sialidase inhibitors 4-amino-4-deoxy-and 4-deoxy-4-guanidino-Neu5Ac2en. J Chem Soc Perkin Trans I 1996, 23: 2811-15.
38. Andrews, D.M., Cherry, P.C., Humber, D.C. et al. Synthesis and influenza virus sialidase inhibitory activity of analogues of 4-guanidino-Neu5Ac2en (zanamivir) modified in the glycerol sidechain. Eur J Med Chem, submitted for publication.
39. Andrews, D., Jones, P., Humber, D. Preparation of dihydropyran neuraminic acid analogs as sialidase and influenza virus inhibitors. WO 9706157.
40. Reece, P.A., Wu, W.-Y., Jin, B., Krippner, G.Y., Watson, K.G. Synthesis and use of immobilized influenza virus sialidase-binding sialic acid-like compounds for detection of influenza virus. WO 9732214.
41. Sollis, S.L., Smith, P.W., Howes, P.D., Cherry, P.C., Bethell, R.C. Novel inhibitors of influenza sialidase related to GG167. Synthesis of 4-amino and guanidino-4H-pyran-2-carboxylic acid-6-propylamides: Selective inhibitors of influenza A virus sialidase. Bioorg Med Chem Lett 1996, 6: 1805-8.
42. Smith, P.W., Sollis, S.L., Howes, P.D. et al. Novel inhibitors of influenza sialidases related to GG167. Structure-activity, crystallographic and molecular dynamics studies with 4H-pyran-2-carboxylic acid 6-carboxamides. Bioorg Med Chem Lett 1996, 6: 2931-6.
43. Smith, P.W., Sollis, S.L., Howes, P.D. et al. Dihydropyrancarboxamides related to zanamivir: A new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino-and 4-amino-4H-pyran-6-carboxamides. J Med Chem 1998, 41: 787-97.
44. Taylor, N.R., Cleasby, A., Singh, O. et al. Dihydropyrancarboxamides related to zanamivir: A new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B. J Med Chem 1998, 41: 798-807.
45. Smith, P.W., Whittington, A.R. Novel inhibitors of influenza sialidases related to zanamivir. Heterocyclic replacements of the glycerol sidechain. Bioorg Med Chem Lett 1997, 7: 2239-42.
46. Williams, M.A., Lew, W., Mendel, D.B. et al. Structure-activity relationships of carbocyclic influenza sialidase inhibitors. Bioorg Med Chem Lett 1997, 7: 1837-42.
47. Lew, W., Williams, M.A., Mendel, D.B., Escarpe, P.A., Kim, C.U. C3-Thia and C3-carba isosteres of a carbocyclic influenza sialidase inhibitor, (3R,4R,5R)-4-acetamido-5-amino-3-propoxy-1-cyclohexene-1-carboxylicacid. Bioorg Med Chem Lett 1997, 7: 1843-46.
48. Zhang, L., Williams, M.A., Mendel, D.B., Escarpe, P.A., Kim, C.U. Synthesis and activity of C2-substituted analogs of influenza sialidase inhibitor GS 4071. Bioorg Med Chem Lett 1997, 7: 1847-50.
49. Wu, H., Lew, W., Williams, M.A. et al. Structure-activity relationships of carbocyclic influenza sialidase inhibitors with increased lipophilicity. 214th ACS Natl Meet (Sept. 7-11, Las Vegas) 1997, MEDI-186.
50. Lew, W., Williams, M.A., Mendel, D.B. et al. A new carbocyclic sialidase inhibitor related to GS4071: (3R,4R,5S)-4-acetamido-5-amino-3-(1-(S)-(2-phenethyl)propoxy)-1-cyclohexene-1- carboxylic acid. 214th ACS Natl Meet (Sept. 7-11, Las Vegas) 1997.
51. Williams, M.A., Kim, C.U., Liu, H. et al. A new class of carbocyclic influenza sialidase inhibitors: Structure-activity relationships. 214th ACS Natl Meet (Sept. 7-11, Las Vegas) 1997.
52. Luo, M., Air, G.M., Brouillette, W.J. Design of aromatic inhibitors of influenza virus sialidase. J Infect Dis 1997, 176(Suppl. 1): S62-5.
53. Brouillette, W.J., Atigadda, V.R., Duarte, F.J. et al. Structure-based benzoic acid inhibitors of influenza sialidase. 214th ACS Natl Meet (Sept. 7-11, Las Vegas) 1997, MEDI-251.
54. Ali, S.M., Babu, Y.S., Bantia, S. et al. Fluoro substituted aromatic inhibitors of influenza sialidase. 213th ACS Natl Meet (Apr. 13-17, San Francisco) 1997, MEDI-277.
55. Williams, M., Bischofberger, N., Swaminathan, S., Kim, C.U. Synthesis and influenza sialidase inhibitory activity of aromatic analogs of sialic acid. Bioorg Med Chem Lett 1995, 5:, 2251-4.
56. Chand, P., Babu, Y.S., Bantia, S. et al. Design and synthesis of benzoic acid derivatives as influenza sialidase inhibitors using structure-based drug design. J Med Chem 1997, 40: 4030-52.
57. Chan, T.-H., Xin, Y.-C., von Itzstein, M. Synthesis of phosphonic acid analogs of sialic scids (Neu5Ac and KDN) as potential sialidase inhibitors. J Org Chem 1997, 62: 3500-4.
58. Babu, Y.S. Potent influenza sialidase inhibitors containing a novel ring structure. 214th ACS Natl Meet (Sept. 7-11, Las Vegas) 1997, MEDI-136.
59. Babu, Y.S., Chand, P., Montgomery, J.A. Preparation of substituted cyclopentanes as influenza virus sialidase inhibitors. WO 9747194.
60. McKimm-B.J.L., Blick, T.J., Sahasrabudhe, A. et al. Generation and characterisation of variants of NWS/G70C influenza virus after in vitro passage in the presence of 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother 1996, 40: 40-6.
61. Sahasrabudhe, A., Blick, T., Mckimm-Breschkin, J. Influenza virus variants resistant to GG167 with mutations in the haemagglutinin. Int Congr Ser 1996, 1123(Options for the Control of Influenza III): 748-52.
62. Penn, C.R., Barnett, J.M., Bethell, R.C. et al. Selection of influenza virus with reduced sensitivity in vitro to the sialidase inhibitor GG167 (4-guanidino-Neu5Ac2en): Changes in hemagglutinin may compensate for loss of sialidase activity. Int Congr Ser 1996, 1123(Options for the Control of Influenza III); 735-40.
63. Ryan, D.M., Ticehurst, J., Dempsey, M.H., Penn, C.R. Inhibition of influenza virus replication in mice by GG167 (2,3-didehydro-2,4-dideoxy-4-guanidino-N-acetylneuraminic acid) is consistent with extracellular activity of viral sialidase (sialidase). Antimicrob Agents Chemother 1994, 38: 2270-5.
64. Woods, J.M., Bethell, R.C., Coates, J.A.V. et al. 4-Guanidino-2,4-dideoxy-2.3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor of both the sialidase (sialidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993, 37: 1473-9.
65. Baum, L.G., Paulson, J.C. Sialyloligosaccharides of the respiratory epithelium in the selection of human influenza virus receptor specificity. Acta Histochem 1990, 40(89, Suppl.): 35-8.
66. Ito, T., Suzuki, Y., Takada, A. et al. Differences in sialic acid-galactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection. J Virol 1997, 71: 3357-62.
67. Weis, W., Brown, J.H., Cusack, S., Paulson, J.C., Skehel, J.J., Wiley, D.C. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature (London) 1988, 333: 426-31.
68. Blick, T.J., Tiong, T., Sahasrabudhe, A. et al. Generation and characterisation of an influenza virus sialidase variant with decreased sensitivity to the sialidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology 1995, 214: 475-84.
69. Blick T.J., Sahasrabudhe, A., McDonald, M. et al. The interaction of haemagglutinin and sialidase mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en. Virology 1998, 246: 95-103.
70. Staschke, K.A., Colacino, J.M., Baxter, A.J. et al. Molecular basis for the resistance of the influenza viruses to 4-guanidino-Neu5Ac2en. Virology 1995, 214: 642-6.
71. McKimm-Breschkin, J.L., McDonald, M., Blick, T.J., Colman, P.M. Mutation in the influenza virus sialidase gene resulting in decreased sensitivity to the sialidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme. Virology 1996, 225: 240-2.
72. Bethell, R.C., Barnett, J.M., Cadman, A., Madar, S.H., Burrell, F.M., Tisdale, M. Submitted for publication.
73. Gubareva, L.V., Bethell, R., Hart, G.J., Murti, K.G., Penn, C.R., Webster, R.G. Characterisation of mutants of influenza A virus selected with the sialidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 1996, 70: 1818-27.
74. Gubareva, L.V., Robinson, M.J., Bethell, R.C., Webster, R.G. Catalytic and framework mutations in the sialidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997, 71: 3385-90.
75. McKimm-Breschkin, J.L., Sahasrabudhe, A., Blick, T.J. et al. Mutations in a conserved residue in the influenza virus sialidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 1998, 72: 2456-62.
76. Barnett, J., Dempsey, M., Tisdale, M., Rothbarth, P.H., de Groot, R., Osterhaus, A.D.M.E. Susceptibility monitoring of influenza virus clinical isolates to the sialidase inhibitor zanamivir (GG167) during phase II clinical efficacy trials. 37th Intersci Conf Antimicrob Agents Chemother (Sept. 28-Oct. 1, Toronto) 1997, Abst H-93.
77. Nicholson, K.G. Use of antivirals in influenza in the elderly: Prophylaxis and therapy. Gerontology 1996, 42; 280-9.
78. Gubareva, L.V., Brenner, M.K., Webster, R.G. Molecular characterisation of influenza B virus from a patient after treatment with a sialidase targetted antiviral. Am Soc Virol Annu Meet, W6-9.